C. Manegold
Heidelberg University · 142 works · 3,598 citations · h-index 26
Top works
- Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- ALIMTA® (pemetrexed disodium) as second-line treatment ofnon-small-cell lung cancer: a phase II study
- Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704
- Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial
- The combined effect of smoking and coffee drinking on LDL and HDL cholesterol.
- Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
- Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975
- Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency
- Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma
- Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent
- Induction treatment before surgery for non-small cell lung cancer
- Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT?
- Aromatic l ‐amino acid decarboxylase deficiency: clinical features, drug therapy and follow‐up
- Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience
- Abstracts of posters
- ROS1 fusions in Chinese patients with non-small-cell lung cancer
- Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy
- A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
- Disseminated testicular cancer with bulky disease: results of a phase‐II study with cisplatin ultra high dose/VP‐16/bleomycin
- Prognostic and predictive factors in a randomized phase III trial comparing cisplatin–pemetrexed versus cisplatin–gemcitabine in advanced non-small-cell lung cancer